SYK and diffuse large B-cell lymphoma: Here, we comparatively evaluated the anti-tumorigenic effect of isoform-specific bivalent BET inhibitor AZD5153 and pan-BET inhibitor I-BET151 in a DLBCL and Burkitt’s lymphoma in vitro approach and further investigated the cell- and molecular effect of simultaneous SYK inhibition by Entospletinib.